Aspire Biopharma Holdings (ASBP) Other Non Operating Income (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Other Non Operating Income of $251807.0 for Q1 2026, up 365.29% year-over-year from $54118.1 in Q1 2025, and down 78.57% quarter-over-quarter from $1.2 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Other Non Operating Income (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Non Operating Income for 2 consecutive years, with $251807.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 365.29% year-over-year to $251807.0; the TTM figure through Mar 2026 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was $810787.0, changed N/A from the prior year.
- Other Non Operating Income retreated to $251807.0 in Q1 2026 per ASBP's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.2 million in Q4 2025 and bottomed at -$289401.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Mn |
| Mar 31, 2026 | 251,807.00 |
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | 775,062.00 |
| Jun 30, 2025 | -289,401.00 |
| Mar 31, 2025 | -94,917.00 |